Rezpegaldesleukin Clinical and Commercial Assessment 2026 with Sales Forecast to 2034

FDA Fast Track status and expansion across atopic dermatitis, alopecia, lupus and type 1 diabetes broaden its autoimmune opportunity

Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Rezpegaldesleukin Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of rezpegaldesleukin's clinical, regulatory and commercial outlook across alopecia areata, atopic dermatitis, systemic lupus erythematosus and type 1 diabetes mellitus. The analysis covers the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.

Key Factors Driving Rezpegaldesleukin Market Growth

• Differentiated regulatory T-cell biology: Rezpegaldesleukin is an advanced regulatory T-cell-expanding biologic in clinical development. Its selective activity through the interleukin-2 receptor pathway is designed to expand and activate regulatory T cells while limiting broad stimulation of pro-inflammatory immune cells. This mechanism may support durable immune modulation across chronic autoimmune and inflammatory diseases.
• Positive Phase IIb results in atopic dermatitis: The global REZOLVE-AD Phase IIb study enrolled 393 patients with moderate-to-severe atopic dermatitis and met its primary and key secondary endpoints. At Week 16, rezpegaldesleukin demonstrated statistically significant improvements over placebo across multiple efficacy measures, including Eczema Area and Severity Index scores and itch reduction. Reported EASI improvements of approximately 53% to 61%, compared with 31% for placebo, support the therapy's potential positioning in the competitive atopic dermatitis market.
• Durable responses with infrequent maintenance dosing: During the 52-week REZOLVE-AD study, approximately 71% to 83% of EASI-75 responders maintained their responses with monthly or quarterly maintenance dosing. A once-quarterly regimen could provide a meaningful administration advantage compared with biologics requiring more frequent treatment.
• FDA Fast Track designations: The U.S. Food and Drug Administration granted Fast Track designation to rezpegaldesleukin for moderate-to-severe atopic dermatitis in February 2025 and severe alopecia areata in July 2025. These designations may support more frequent regulatory engagement and an accelerated development pathway.
• Expansion into alopecia areata: In the Phase IIb REZOLVE-AA study, patients with severe alopecia areata achieved mean Severity of Alopecia Tool score reductions of approximately 28% to 30%, compared with 11% for placebo at Week 36. Nektar Therapeutics reported that the efficacy and safety findings support advancement into Phase III development.

Recent Rezpegaldesleukin Developments

In March 2026, Nektar Therapeutics presented rezpegaldesleukin data at the American Academy of Dermatology Annual Meeting. Results from the global REZOLVE-AD study were presented by Dr. Raj Chovatiya during an oral poster session focused on Phase IIb efficacy, safety and baseline severity-dependent treatment response in moderate-to-severe atopic dermatitis.

The presentation reinforced the clinical relevance of rezpegaldesleukin's regulatory T-cell-directed approach and highlighted its potential to provide sustained disease control with extended maintenance intervals. Continued clinical development in atopic dermatitis and alopecia areata may broaden the product's long-term commercial opportunity within the global immunology market.

Rezpegaldesleukin Drug Overview

Rezpegaldesleukin, also known as REZPEG and formerly designated NKTR-358, is an investigational polyethylene glycol-conjugated interleukin-2 cytokine agonist developed by Nektar Therapeutics . Administered by subcutaneous injection, the therapy is engineered for preferential binding to the interleukin-2 receptor complex and selective expansion of regulatory T cells.

Clinical development has generated evidence of sustained regulatory T-cell expansion, encouraging efficacy and a generally favorable safety profile. Rezpegaldesleukin's differentiated mechanism, potential dosing flexibility and applicability across multiple immune-mediated disorders position it as a prospective first-in-class therapy. It remains investigational and has not received marketing approval.

Scope of the Rezpegaldesleukin Market Report

• Current and forecasted rezpegaldesleukin sales through 2034 across the seven major markets.
• Market size and revenue forecasts for atopic dermatitis, alopecia areata, systemic lupus erythematosus and type 1 diabetes mellitus.
• Analysis of mechanism of Action , dosage, administration and clinical development.
• Clinical trial assessment covering interventions, study status and anticipated completion timelines.
• Regulatory milestones, Fast Track designations and expected commercialization timelines.
• Pricing, reimbursement, cost estimates and geographic variations.
• Patent coverage, potential generic entry and implications for future pricing.
• Competitive intelligence, pipeline analysis and late-stage emerging therapies.
• SWOT analysis and expert perspectives on market positioning.
• Commercial partnerships, licensing agreements, mergers and acquisitions.

Market Potential and Competitive Landscape

The report evaluates rezpegaldesleukin's projected market size, peak sales potential, pricing strategy and reimbursement environment. It also compares the product's clinical and commercial profile with marketed treatments and emerging therapies across its Target indications.

Competitive intensity is expected to increase as new products advance in atopic dermatitis, alopecia areata and other immunological conditions. Rezpegaldesleukin's market performance will depend on Phase III outcomes, regulatory progress, safety, durability of response, dosing convenience, payer acceptance and differentiation from established standards of care.

Key Strategic Questions Addressed

• What are rezpegaldesleukin's mechanism, route of administration and clinical differentiators?
• What is the therapy's development status across each potential indication?
• How could FDA designations influence development and market entry?
• What are the forecasted rezpegaldesleukin sales in the United States, Europe and Japan through 2034?
• Which assumptions support the market size and revenue forecasts?
• How does rezpegaldesleukin compare with existing treatments and late-stage pipeline competitors?
• What pricing, reimbursement and cost-effectiveness factors may influence adoption?
• Which collaborations, licensing transactions and corporate activities could affect commercialization?

The report supports pharmaceutical companies, investors, healthcare consultants and strategic decision-makers by providing an integrated view of rezpegaldesleukin's sales outlook, growth drivers, development risks and competitive position. Its forecast through 2034 offers actionable intelligence for portfolio planning, market assessment and investment analysis within the evolving immunology landscape.

Key Topics Covered

1. Report Introduction

2. Rezpegaldesleukin Overview in potential indication like Alopecia areata, Atopic dermatitis, Systemic lupus erythematosus, and Type 1 diabetes mellitus
2.1. Product Detail
2.2. Rezpegaldesleukin Clinical Development
2.2.1. Rezpegaldesleukin Clinical studies
2.2.2. Rezpegaldesleukin Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile

3. Rezpegaldesleukin Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Rezpegaldesleukin Therapies)

5. Rezpegaldesleukin Market Assessment
5.1. Rezpegaldesleukin Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Rezpegaldesleukin Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Rezpegaldesleukin Market Size in the United States for potential indications
5.3.2. Rezpegaldesleukin Market Size in Germany for potential indications
5.3.3. Rezpegaldesleukin Market Size in France for potential indications
5.3.4. Rezpegaldesleukin Market Size in Italy for potential indications
5.3.5. Rezpegaldesleukin Market Size in Spain for potential indications
5.3.6. Rezpegaldesleukin Market Size in the United Kingdom for potential indications
5.3.7. Rezpegaldesleukin Market Size in Japan for potential indications

6. Rezpegaldesleukin SWOT Analysis

7. Analysts' Views

8. Appendix
8.1. Bibliography
8.2. Report Methodology

List of Tables
Table 1: Rezpegaldesleukin, Clinical Trial Description, 2023
Table 2: Rezpegaldesleukin, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Rezpegaldesleukin's pricing and cost Assumptions
Table 6: Rezpegaldesleukin's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Rezpegaldesleukin Market Size in the US, in USD million (2020-2034)
Table 8: Rezpegaldesleukin Market Size in Germany, in USD million (2020-2034)
Table 9: Rezpegaldesleukin Market Size in France, in USD million (2020-2034)
Table 10: Rezpegaldesleukin Market Size in Italy, in USD million (2020-2034)
Table 11: Rezpegaldesleukin Market Size in Spain, in USD million (2020-2034)
Table 12: Rezpegaldesleukin Market Size in the UK, in USD million (2020-2034)
Table 13: Rezpegaldesleukin Market Size in Japan, in USD million (2020-2034)

List of Figures
Figure 1: Rezpegaldesleukin's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Rezpegaldesleukin Market Size in the United States, USD million (2020-2034)
Figure 3: Rezpegaldesleukin Market Size in Germany, USD million (2020-2034)
Figure 4: Rezpegaldesleukin Market Size in France, USD million (2020-2034)
Figure 5: Rezpegaldesleukin Market Size in Italy, USD million (2020-2034)
Figure 6: Rezpegaldesleukin Market Size in Spain, USD million (2020-2034)
Figure 7: Rezpegaldesleukin Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Rezpegaldesleukin Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/r48edk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900